UNL wins $4M bird-flu grant

Why it matters

The University of Nebraska-Lincoln’s new $4 million federal grant and NanoViricides’ claim that an Ebola antiviral is ready for shipment point to the same reality: outbreak countermeasures are still mostly in development, not sitting in warehouses. The Nebraska award will fund a five-year effort led by virologist Eric Weaver to push a broader influenza vaccine toward protection against multiple high-risk avian strains, including bird-flu variants with pandemic potential. NanoViricides, in a May 26 statement, said its drug candidate NV-387 could be deployed to the Democratic Republic of the Congo during the current Bundibugyo Ebola emergency and could enter Phase II trials. ### What exactly did Nebraska win, and who is leading it? The National Institutes of Health awarded the University of Nebraska-Lincoln a $4 million, five-year grant for work led by Eric Weaver, director of the Nebraska Center for Virology, according to the university and Nebraska Public Media. The project is aimed at a vaccine that could provide broad, durable immunity across multiple high-risk avian influenza strains rather than matching one circulating strain at a time. (news.unl.edu) Weaver’s team is building on its Epigraph vaccine strategy, which the university said had previously shown broader cellular immunity than traditional flu vaccines in earlier work. The approach targets both fast-changing surface proteins and more stable viral components, a design the university said is intended to widen protection against viruses with pandemic potential. (news.unl.edu) ### Why is bird flu part of this project? Nebraska Public Media reported that the grant is focused on strains that health officials say could trigger the next pandemic, including bird-flu variants. The point of the work is not a seasonal flu update but a vaccine platform that could hold up across several dangerous avian strains. (news.unl.edu) Prior reporting on Weaver’s research said the Epigraph method analyzed thousands of influenza sequences to identify common immune targets. That earlier work was presented as support for a broader “universal” influenza strategy, though the current grant is for continued research rather than a commercial rollout. ### Where does NanoViricides fit into this story? (nebraskapublicmedia.org) NanoViricides said on May 26 that NV-387 was “ready to be shipped” to the Democratic Republic of the Congo for the Ebola emergency. The company said the drug candidate could be evaluated against the Bundibugyo strain and said it could move into a Phase II clinical trial. The World Health Organization said on May 17 that the Ebola outbreak caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constituted a Public Health Emergency of International Concern. (news.unl.edu) Africa CDC said the DRC had declared the outbreak on May 15 after laboratory-confirmed cases in Ituri province, alongside a much larger pool of suspected cases. (nanoviricides.com) ### Does NV-387 mean there is an approved Ebola treatment ready now? NanoViricides’ statement described NV-387 as a candidate treatment, not an approved therapy. The company’s announcement is a deployment claim tied to an emergency and a possible next-stage trial, rather than evidence of a stockpiled, licensed product already in routine use. The Centers for Disease Control and Prevention said the Bundibugyo species has no approved therapies specifically established for that strain and noted the outbreak is the 17th recorded Ebola outbreak in the DRC since 1976. (who.int) That leaves public-health officials balancing outbreak response with experimental or developing tools. ### So what do these two developments show about preparedness? (nanoviricides.com) The Nebraska grant shows federal money moving into earlier-stage vaccine research, while the NanoViricides announcement shows a company trying to position an investigational antiviral for emergency use during an active outbreak. Both are concrete signs of scientific and clinical activity, but both are still upstream from large-scale manufacturing, stockpiling and broad distribution. That conclusion is an inference from the status of the two efforts: one is a five-year research grant, and the other is a company statement about a candidate drug and a possible Phase II trial. (cdc.gov) The next visible milestones are also developmental. Weaver’s NIH-backed project runs over five years at the University of Nebraska-Lincoln, and NanoViricides said NV-387 could proceed to Phase II testing as the Bundibugyo outbreak response continues in the Democratic Republic of the Congo and Uganda. (news.unl.edu)

Key numbers

• University of Nebraska-Lincoln researchers received a $4 million NIH grant in May 2026 to advance a vaccine targeting multiple high-risk avian influenza strains.
• The grant backs virologist Eric Weaver’s five-year Epigraph project, while NanoViricides said on May 26 NV-387 was ready for shipment to Congo.
• Next, Weaver’s team will continue NIH-funded vaccine work, and NanoViricides said NV-387 could move into Phase II testing.
• The University of Nebraska-Lincoln’s new $4 million federal grant and NanoViricides’ claim that an Ebola antiviral is ready for shipment point to the same reality: outbreak countermeasures are still mostly in development, not sitting in warehouses.

What happens next

• The Nebraska award will fund a five-year effort led by virologist Eric Weaver to push a broader influenza vaccine toward protection against multiple high-risk avian strains, including bird-flu variants with pandemic potential.
• NanoViricides, in a May 26 statement, said its drug candidate NV-387 could be deployed to the Democratic Republic of the Congo during the current Bundibugyo Ebola emergency and could enter Phase II trials.
• The project is aimed at a vaccine that could provide broad, durable immunity across multiple high-risk avian influenza strains rather than matching one circulating strain at a time.

Sources

• news.unl.edu
• nebraskapublicmedia.org
• nanoviricides.com
• who.int
• cdc.gov

Quick answers